跳转至内容
Merck
CN

SML1796

Sigma-Aldrich

阿扎那韦

≥98% (HPLC)

别名:

1,14-二甲基(3S,8S,9S,12S)-3,12-双(1,1-二甲基乙基)-8-羟基-4,11-二氧代-9-(苯甲基)-6-[[4- (2-吡啶基)苯基]甲基] -2,5,6,10,13-五叠氮丙二酸酯, BMS-232632

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C38H52N6O7
分子量:
704.86
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

旋光性

[α]/D -41 to -49°, c = 0.1 in ethanol

颜色

white to beige

溶解性

DMSO: 10 mg/mL, clear

储存温度

−20°C

SMILES字符串

O=C(N[C@@H](C(C)(C)C)C(N[C@H]([C@H](CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC([C@@H](NC(OC)=O)C(C)(C)C)=O)O)CC3=CC=CC=C3)=O)OC

InChI

1S/C38H52N6O7/c1-37(2,3)31(41-35(48)50-7)33(46)40-29(22-25-14-10-9-11-15-25)30(45)24-44(43-34(47)32(38(4,5)6)42-36(49)51-8)23-26-17-19-27(20-18-26)28-16-12-13-21-39-28/h9-21,29-32,45H,22-24H2,1-8H3,(H,40,46)(H,41,48)(H,42,49)(H,43,47)/t29-,30-,31+,32+/m0/s1

InChI key

AXRYRYVKAWYZBR-GASGPIRDSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

阿扎那韦抑制人免疫缺陷病毒中 gag 和 gag-pol 多蛋白的裂解。它被肝脏中的细胞色素 P450 吸收和代谢。它具有最小的副作用,并且对胰岛素敏感性和血清脂质谱没有影响。

生化/生理作用

阿扎那韦是一种抗病毒 HIV 蛋白酶抑制剂。

象形图

Exclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Daniel W Cole et al.
Experimental cell research, 382(1), 111386-111386 (2019-05-11)
Many FDA-approved anti-cancer therapies, targeted toward a wide array of molecular targets and signaling networks, have been demonstrated to activate the unfolded protein response (UPR). Despite a critical role for UPR signaling in the apoptotic execution of cancer cells by
Saif Ahmad Khan et al.
Pharmaceutics, 12(11) (2020-11-12)
Atazanavir (ATZ) presents poor brain availability when administered orally, which poses a major hurdle in its use as an effective therapy for the management of NeuroAIDS. The utilization of nanostructured lipid carriers (NLCs) in conjunction with the premeditated use of
Atazanavir
Croom KF, et al.
Drugs, 69(8), 1107-1140 (2009)
Atazanavir: new option for treatment of HIV infection
Havlir DV and O'marro SD
Clinical Infectious Diseases, 38(11), 1599-1604 (2004)
Jayanta Roy-Chowdhury et al.
Clinical pharmacology in drug development, 6(2), 140-146 (2017-03-07)
Hyperbilirubinemia is a common finding in individuals with a history of substance abuse. Although this may indicate a serious disorder of liver function, this is not always the case. An understanding of bilirubin formation, metabolism, and transport can provide a

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门